Digene wins HPV (human papillomavirus) deal extension with Quest:
This article was originally published in Clinica
Executive Summary
Gaithersburg, Maryland-based molecular diagnostics company Digene is to supply diagnostic testing service provider Quest Diagnostics with products related to human papillomavirus (HPV) testing for an additional four years. The new agreement, an extension to an existing three-year supply deal, will see Lyndhurst, New Jersey-based Quest running Digene's HPV test, said to be the only FDA-approved test for high-risk types of the cervical cancer-related virus, on the latter's Rapid Capture automated, high-thoroughput analyser.